![](https://www.molecular-medicine-israel.co.il/wp-content/uploads/2020/08/syringe-injection-medical-needle-300x200.jpg)
Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans
Vaccine protection profile Cytomegalovirus (CMV) is a leading cause of posttransplant complications and congenital infections, but there are no CMV vaccines currently licensed. Jenks et al. characterized